Privia Health Group, Inc. (NASDAQ:PRVA) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. cut its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 25.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 167,498 shares of the company's stock after selling 56,744 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.14% of Privia Health Group worth $3,857,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tower Research Capital LLC TRC increased its position in shares of Privia Health Group by 171.1% in the first quarter. Tower Research Capital LLC TRC now owns 1,578 shares of the company's stock worth $44,000 after purchasing an additional 996 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Privia Health Group in the first quarter worth approximately $47,000. Neo Ivy Capital Management bought a new position in shares of Privia Health Group in the second quarter worth approximately $53,000. Benjamin Edwards Inc. bought a new position in shares of Privia Health Group in the second quarter worth approximately $58,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Privia Health Group in the fourth quarter worth approximately $72,000. 94.48% of the stock is currently owned by institutional investors.

Privia Health Group Trading Up 0.9 %

Shares of NASDAQ:PRVA traded up $0.16 during trading on Wednesday, reaching $17.85. 955,801 shares of the company traded hands, compared to its average volume of 964,611. The business's fifty day moving average is $20.20 and its 200-day moving average is $21.46. Privia Health Group, Inc. has a 52-week low of $17.54 and a 52-week high of $30.15. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of 93.95, a P/E/G ratio of 2.51 and a beta of 0.81.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The business had revenue of $440.80 million during the quarter, compared to analysts' expectations of $425.81 million. During the same period in the previous year, the business earned $0.14 EPS. The business's revenue was up 21.0% compared to the same quarter last year. On average, sell-side analysts predict that Privia Health Group, Inc. will post 0.26 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PRVA shares. UBS Group decreased their price objective on shares of Privia Health Group from $31.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, March 1st. Truist Financial cut their target price on Privia Health Group from $32.00 to $28.00 and set a "buy" rating for the company in a research note on Thursday, February 29th. Jefferies Financial Group initiated coverage on Privia Health Group in a research note on Monday, February 26th. They issued a "buy" rating and a $25.00 target price for the company. Bank of America lowered Privia Health Group from a "buy" rating to a "neutral" rating and cut their target price for the stock from $27.00 to $21.00 in a research note on Thursday, February 22nd. Finally, Barclays initiated coverage on Privia Health Group in a research note on Wednesday, March 6th. They issued an "equal weight" rating and a $22.00 target price for the company. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.18.

Insider Buying and Selling

In related news, CFO David Mountcastle sold 3,933 shares of the firm's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $17.77, for a total value of $69,889.41. Following the completion of the sale, the chief financial officer now owns 262,279 shares of the company's stock, valued at $4,660,697.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Privia Health Group news, Director William M. Sullivan sold 9,951 shares of the stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $23.03, for a total value of $229,171.53. Following the completion of the transaction, the director now owns 5,464,533 shares in the company, valued at $125,848,194.99. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO David Mountcastle sold 3,933 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $17.77, for a total value of $69,889.41. Following the completion of the transaction, the chief financial officer now owns 262,279 shares of the company's stock, valued at approximately $4,660,697.83. The disclosure for this sale can be found here. 14.20% of the stock is currently owned by insiders.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.